Compare · ASLE vs EW
ASLE vs EW
Side-by-side comparison of AerSale Corporation (ASLE) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- ASLE operates in Consumer Discretionary, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $50.78B, about 226.9x ASLE ($223.8M).
- EW has been more active in the news (5 items in the past 4 weeks vs 2 for ASLE).
- EW has more recent analyst coverage (25 ratings vs 6 for ASLE).
- Company
- AerSale Corporation
- Edwards Lifesciences Corporation
- Price
- $4.75+1.06%
- $86.61-1.66%
- Market cap
- $223.8M
- $50.78B
- 1M return
- -13.32%
- -
- 1Y return
- -34.44%
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 2
- 5
- Recent ratings
- 6
- 25
AerSale Corporation
AerSale Corporation provides aftermarket commercial aircraft, engines, and its parts to passenger and cargo airlines, leasing companies, original equipment manufacturers, and government and defense contractors, as well as maintenance, repair, and overhaul (MRO) service providers worldwide. It operates in two segments, Asset Management Solutions and Technical Operations (TechOps). The Asset Management Solutions segment engages in the sale and lease of aircraft, engines, and airframes, as well as disassembly of these assets for component parts. The TechOps segment provides internal and third-party aviation services, including internally developed engineered solutions, heavy aircraft maintenance and modification, and component MRO, as well as storage and disassembly services. This segment also provides aircraft modifications, cargo/tanker conversions of aircraft, and aircraft storage; and MRO services for landing gear, thrust reversers, hydraulic systems, and other aircraft components. The company was founded in 2008 and is headquartered in Coral Gables, Florida.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest ASLE
- AerSale® Leases 757-200PCF Freighter to Mister Air for Its Specialized Cargo Network
- AerSale Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- AerSale® Announces Boeing 757-200PCF Freighter Lease to Jupiter Jet
- Officer Tschirhart Benjamin Thomas sold $4,797 worth of shares (882 units at $5.44) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 46,769 units (SEC Form 4) to cover taxes
- Officer Finazzo Nicolas was granted 259,965 shares, increasing direct ownership by 60% to 694,434 units (SEC Form 4)
- Officer Garmendia Martin was granted 29,246 shares, increasing direct ownership by 16% to 212,623 units (SEC Form 4)
- Officer Hechenberger Paul Andrew was granted 29,246 shares, increasing direct ownership by 201% to 43,827 units (SEC Form 4)
- Officer Jones Gary Edmund was granted 32,495 shares, increasing direct ownership by 20% to 194,900 units (SEC Form 4)
- Chief Information Officer Pizzi Enrique was granted 15,164 shares, increasing direct ownership by 19% to 96,388 units (SEC Form 4)
- Officer Tschirhart Benjamin Thomas was granted 15,164 shares, increasing direct ownership by 47% to 47,651 units (SEC Form 4)
Latest EW
- SEC Form 4 filed by Edwards Lifesciences Corporation
- Barclays initiated coverage on Edwards Lifesciences with a new price target
- Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- Edwards Lifesciences to Host Investor Event in Conjunction With TCT
- Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision